Analysen von Michael J. Yee
28.02.12 | Human Genome Sciences sector perform | RBC Capital Markets | |
27.02.12 | Auxilium Pharmaceuticals outperform | RBC Capital Markets | |
24.02.12 | Celgene outperform | RBC Capital Markets | |
24.02.12 | Dendreon sector perform | RBC Capital Markets | |
23.02.12 | Gilead Sciences outperform | RBC Capital Markets | |
23.02.12 | Human Genome Sciences sector perform | RBC Capital Markets | |
17.02.12 | Biomarin Pharmaceutical outperform | RBC Capital Markets | |
17.02.12 | Biogen outperform | RBC Capital Markets | |
Werbung
|
|||
16.02.12 | Auxilium Pharmaceuticals outperform | RBC Capital Markets | |
16.02.12 | Gilead Sciences outperform | RBC Capital Markets | |
13.02.12 | Biomarin Pharmaceutical outperform | RBC Capital Markets | |
09.02.12 | Elan outperform | RBC Capital Markets | |
09.02.12 | InterMune outperform | RBC Capital Markets | |
06.02.12 | Gilead Sciences outperform | RBC Capital Markets | |
02.02.12 | Elan outperform | RBC Capital Markets | |
02.02.12 | Biogen outperform | RBC Capital Markets | |
30.01.12 | Amgen outperform | RBC Capital Markets | |
26.01.12 | Myriad Genetics outperform | RBC Capital Markets | |
25.01.12 | Gilead Sciences outperform | RBC Capital Markets | |
23.01.12 | Biogen outperform | RBC Capital Markets | |
23.01.12 | Cubist Pharmaceuticals outperform | RBC Capital Markets | |
20.01.12 | Gilead Sciences outperform | RBC Capital Markets | |
19.01.12 | Xoma outperform | RBC Capital Markets | |
19.01.12 | Amgen outperform | RBC Capital Markets | |
19.01.12 | Auxilium Pharmaceuticals outperform | RBC Capital Markets | |
18.01.12 | Celgene outperform | RBC Capital Markets | |
18.01.12 | Regeneron Pharmaceuticals outperform | RBC Capital Markets | |
13.01.12 | Human Genome Sciences outperform | RBC Capital Markets | |
11.01.12 | Regeneron Pharmaceuticals outperform | RBC Capital Markets | |
11.01.12 | Dendreon sector perform | RBC Capital Markets | |
12.12.11 | Celgene outperform | RBC Capital Markets | |
08.12.11 | ImmunoGen outperform | RBC Capital Markets | |
08.12.11 | Amgen outperform | RBC Capital Markets | |
06.12.11 | Elan outperform | RBC Capital Markets | |
06.12.11 | Cubist Pharmaceuticals outperform | RBC Capital Markets | |
01.12.11 | Celgene outperform | RBC Capital Markets | |
28.11.11 | Gilead Sciences outperform | RBC Capital Markets | |
21.11.11 | Regeneron Pharmaceuticals outperform | RBC Capital Markets | |
16.11.11 | Gilead Sciences outperform | RBC Capital Markets | |
15.11.11 | Regeneron Pharmaceuticals outperform | RBC Capital Markets | |
15.11.11 | Elan outperform | RBC Capital Markets | |
14.11.11 | Biogen outperform | RBC Capital Markets | |
07.11.11 | Vertex Pharmaceuticals sector perform | RBC Capital Markets | |
03.11.11 | Celgene outperform | RBC Capital Markets | |
03.11.11 | Vertex Pharmaceuticals outperform | RBC Capital Markets | |
03.11.11 | Dendreon sector perform | RBC Capital Markets | |
02.11.11 | Auxilium Pharmaceuticals sector perform | RBC Capital Markets | |
28.10.11 | Human Genome Sciences outperform | RBC Capital Markets | |
26.10.11 | Cubist Pharmaceuticals outperform | RBC Capital Markets | |
26.10.11 | Amgen outperform | RBC Capital Markets |